Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Wyeth signs with Progenics and Exelixis
January 2, 2006
| A version of this story appeared in
Volume 84, Issue 1
Wyeth has agreed to jointly develop Progenics Pharmaceuticals' methylnaltrexone for the treatment of opioid-induced side effects. In exchange for worldwide rights to the drug, Wyeth is paying Progenics $60 million up front and as much as $356.5 million in additional milestone payments. Separately, Wyeth has signed a licensing agreement with Exelixis under which it will assume responsibility for Exelixis compounds targeting the farnesoid X receptor, a nuclear hormone receptor implicated in metabolic and liver disorders. Exelixis will get $10 million up front and may receive up to $147.5 million more in milestone payments.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter